As part of its strategy to back early-stage startups, Simya VC, launched by 212, has invested $500,000 in reprai, a technology venture set to transform marketing and sales in the pharmaceutical industry.
reprai is focused on scalable growth across Europe and the U.S. and will leverage this funding to expand its market share, grow its team, and enhance its technology, positioning itself among the key players shaping global industry standards.
By making interactions between pharmaceutical companies and healthcare professionals more personalized and data-driven, reprai aims to spearhead the digital transformation of the sector. The company deploys AI-powered solutions to optimize pharma marketing channels while developing scalable engagement models that deliver more effective access to healthcare professionals.
Reducing the Cost from $500 to Under $20
Selma Bahçıvanoğlu, Managing Partner at Simya VC, said:
“At Simya VC, we continue to invest in the technologies of the future. Our latest investment, reprai, addresses a critical transformation need in the pharmaceutical industry with its AI-driven engagement platform… In the U.S., a typical doctor-representative meeting costs around $500, whereas reprai reduces this cost to under $20—demonstrating huge potential in terms of scalability and efficiency.”
Didem Aral, Co-Founder and CEO of reprai, added:
“We founded reprai to bring AI-driven transformation to pharma marketing processes. With this investment, we aim to deepen our impact quickly and become one of the players shaping global standards.”
